Sanam Loghavi

List of Publications by Year
in descending order

171 papers	5,380 citations	117453 34 h-index	110170 64 g-index
174 all docs	174 docs citations	174 times ranked	5006 citing authors

#	Article	IF	Citations
1	Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplantation, 2022, 57, 370-376.	1.3	8
2	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer Journal, 2022, 12, 10.	2.8	48
3	<scp>Nonâ€coding NOTCH1</scp> mutations in chronic lymphocytic leukemia negatively impact prognosis. American Journal of Hematology, 2022, 97, .	2.0	1
4	Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leukemia Research, 2022, 116, 106827.	0.4	1
5	Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia, 2022, 36, 1343-1350.	3.3	23
6	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 2022, 28, 557-567.	15.2	26
7	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. American Journal of Hematology, 2022, 97, 865-876.	2.0	12
8	TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood, 2022, 140, 58-72.	0.6	46
9	Essential thrombocythemia complicating hemoglobin SC disease and presenting with priapism. Blood, 2022, 139, 2258-2258.	0.6	0
10	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. American Journal of Hematology, 2022, 97, 885-894.	2.0	4
11	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematology,the, 2022, 9, e350-e360.	2.2	26
12	Hypomethylating agent and venetoclax with FLT3 inhibitor â€œtripletâ€•therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer Journal, 2022, 12, 77.	2.8	33
13	Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Modern Pathology, 2022, 35, 1212-1219.	2.9	10
14	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discovery, 2022, 3, 385-393.	2.6	29
15	Venetoclax combined with <scp>FLAGâ€IDA</scp> induction and consolidation in newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2022, 97, 1035-1043.	2.0	31
16	Major Clinical Response in a Patient with Leukemia Cutis Treated with the Bromodomain Inhibitor PLX51107 and Azacitidine. Leukemia Research, 2022, 119, 106884.	0.4	1
17	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂNeoplasms. Leukemia, 2022, 36, 1703-1719.	3.3	1,211
18	Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica, 2021, 106, 1047-1055.	1.7	40

#	Article	IF	Citations
19	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. Haematologica, 2021, 106, 1120-1128.	1.7	37
20	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E50-E53.	2.0	8
21	Ovarian mucinous neoplasms, intestinal type, in premenopausal patients, develop in abnormal ovaries. Human Pathology, 2021, 108, 32-41.	1.1	2
22	Treating Rosaiâ€“Dorfman disease and RASâ€associated autoimmune leucoproliferative disorder with malignant transformation. British Journal of Haematology, 2021, 192, 667-671.	1.2	2
23	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. Blood Cancer Discovery, 2021, 2, 125-134.	2.6	50
24	Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience. Modern Pathology, 2021, 34, 854-861.	2.9	9
25	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3 â€ITD and IDH mutations. Cancer, 2021, 127, 381-390.	2.0	10
26	Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. Modern Pathology, 2021, 34, 300-313.	2.9	6
27	The Implementation and Effectiveness of PathElective.com. Academic Pathology, 2021, 8, 23742895211006829.	0.7	13
28	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1â€mutated acute myeloid leukaemia. British Journal of Haematology, 2021, 192, 1054-1063.	1.2	28
29	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 25.	2.8	85
30	Decitabine and venetoclax for <scp>IDH1/2</scp>â€mutated acute myeloid leukemia. American Journal of Hematology, 2021, 96, E154-E157.	2.0	19
31	Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Modern Pathology, 2021, 34, 1143-1152.	2.9	12
32	Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Advances, 2021, 5, 2173-2183.	2.5	35
33	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer, 2021, 127, 3113-3124.	2.0	5
34	Clonal haematopoiesis of emerging significance. Pathology, 2021, 53, 300-311.	0.3	9
35	<scp>FLT3</scp> inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed <scp>Acute Myeloid Leukemia</scp> with very low <scp>FLT3</scp> allelic burden. American Journal of Hematology, 2021, 96, E275-E279.	2.0	3
36	Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis â€" Chronic Myelomonocytic Leukemia and Beyond. Current Hematologic Malignancy Reports, 2021, 16, 286-303.	1.2	0

#	Article	IF	Citations
37	Chronic Myelomonocytic Leukemia: Hematopathology Perspective. Journal of Immunotherapy and Precision Oncology, 2021, 4, 142-149.	0.6	1
38	A phase 1b/2 study of azacitidine with PDâ€L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer, 2021, 127, 3761-3771.	2.0	34
39	Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood, 2021, 138, 1733-1739.	0.6	19
40	Future of Education or Present Reality?. Archives of Pathology and Laboratory Medicine, 2021, 145, 1350-1354.	1.2	4
41	Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. Leukemia and Lymphoma, 2021, 62, 3296-3299.	0.6	3
42	Outcomes of TP53â€mutant acute myeloid leukemia with decitabine and venetoclax. Cancer, 2021, 127, 3772-3781.	2.0	80
43	Development of <scp>TP53</scp> mutations over the course of therapy for acute myeloid leukemia. American Journal of Hematology, 2021, 96, 1420-1428.	2.0	10
44	Bâ€cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early Tâ€cell precursor acute lymphoblastic leukaemia/lymphoma (ETPâ€ALL/LBL) from other subtypes of Tâ€cell ALL/LBL. British Journal of Haematology, 2021, 194, 1034-1038.	1.2	9
45	Hematogones with light chain restriction: A potential diagnostic pitfall when using flow cytometry analysis to assess bone marrow specimens. Leukemia Research, 2021, 111, 106704.	0.4	2
46	Elevating Twitter-Based Journal Club Discussions by Leveraging a Voice-Based Platform: #HemepathJC Meets Clubhouse. Current Hematologic Malignancy Reports, 2021, 16, 418-421.	1.2	2
47	Poster: AML-204: Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S213.	0.2	0
48	AML-291: Treatment Response and Outcome in DNMT3A-mutated Acute Myeloblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S301-S302.	0.2	0
49	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 2768-2778.	0.8	173
50	Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. Blood, 2021, 138, 370-370.	0.6	6
51	Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia. Blood, 2021, 138, 2374-2374.	0.6	0
52	Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML. Blood, 2021, 138, 607-607.	0.6	1
53	Outcomes in Advanced-Stage Plasmablastic Lymphoma. Blood, 2021, 138, 2519-2519.	0.6	0
54	Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Blood, 2021, 138, 701-701.	0.6	4

#	Article	IF	Citations
55	NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). Blood, 2021, 138, 2287-2287.	0.6	0
56	A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation. Blood, 2021, 138, 4436-4436.	0.6	3
57	Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML. Blood, 2021, 138, 798-798.	0.6	5
58	Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. Blood, 2021, 138, 371-371.	0.6	41
59	De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leukemia and Lymphoma, 2020, 61, 328-336.	0.6	7
60	A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. Modern Pathology, 2020, 33, 367-379.	2.9	29
61	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphiaâ€negative Bâ€cell acute lymphoblastic leukemia is a strong predictor for survival. American Journal of Hematology, 2020, 95, 144-150.	2.0	25
62	Immunopathology of Kikuchiâ€“Fujimoto disease: A reappraisal using novel immunohistochemistry markers. Histopathology, 2020, 77, 262-274.	1.6	14
63	RAS and TP53 can predict survival in adults with Tâ€cell lymphoblastic leukemia treated with hyperâ€CVAD. Cancer Medicine, 2020, 9, 849-858.	1.3	9
64	Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nature Communications, 2020, 11, 5327.	5.8	208
65	Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. British Journal of Haematology, 2020, 191, e10-e13.	1.2	2
66	Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leukemia and Lymphoma, 2020, 61, 3243-3246.	0.6	3
67	Histology of the normal ovary in premenopausal patients. Annals of Diagnostic Pathology, 2020, 46, 151475.	0.6	6
68	Emergence of BCRâ€“ABL1 Fusion in AML Postâ€“FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance â€“ A Case Series. Frontiers in Oncology, 2020, 10, 588876.	1.3	13
69	Social Media for Hematopathologists: Medical Practice Reinventedâ€”#Hemepath. Current Hematologic Malignancy Reports, 2020, 15, 383-390.	1.2	9
70	Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer Journal, 2020, 10, 86.	2.8	10
71	Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. American Journal of Surgical Pathology, 2020, 44, 1235-1243.	2.1	21
72	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. American Journal of Hematology, 2020, 95, E313-E315.	2.0	4

#	Article	IF	Citations
73	MPN-402: Delayed Resolution of Bone Marrow Morphological Changes of Myelofibrosis Following Successful Stem Cell Transplant and Molecular Clearance of Disease: A Cautionary Tale. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S340-S341.	0.2	0
74	Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Modern Pathology, 2020, 33, 1678-1689.	2.9	16
75	Systematic use of fluorescence inâ€situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms. Histopathology, 2020, 76, 1042-1054.	1.6	13
76	Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Advances, 2020, 4, 1670-1677.	2.5	24
77	Marked paraneoplastic leukemoid reaction in a patient with mesothelioma mimicking a myeloid neoplasm. Blood, 2020, 135, 457-457.	0.6	2
78	Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood, 2020, 135, 791-803.	0.6	412
79	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Advances, 2020, 4, 1311-1320.	2.5	106
80	t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?. Annals of Hematology, 2020, 99, 487-500.	0.8	6
81	Posttransplant Lymphoproliferative Disorder Involving the Gastrointestinal Tract. Journal of Digestive Endoscopy, 2020, 11, 293-294.	0.1	1
82	A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1300-1304.	2.3	4
83	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Advances, 2020, 4, 5716-5721.	2.5	9
84	MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 37-48.	0.6	54
85	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3â€internal tandem duplication mutationâ€“positive acute myeloid leukemia. Cancer, 2019, 125, 3755-3766.	2.0	38
86	Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer. Current Hematologic Malignancy Reports, 2019, 14, 358-367.	1.2	13
87	Association of gene mutations with timeâ€toâ€first treatment in 384 treatmentâ€naive chronic lymphocytic leukaemia patients. British Journal of Haematology, 2019, 187, 307-318.	1.2	26
88	Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Surgical Pathology Clinics, 2019, 12, 651-669.	0.7	1
89	Prognostic significance of baseline FLT3â€ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. American Journal of Hematology, 2019, 94, 984-991.	2.0	32
90	Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent <scp>CD</scp>33 expression and in vitro response to targeted <scp>CD</scp>33 therapy. British Journal of Haematology, 2019, 186, 538-548.	1.2	21

#	Article	IF	Citations
91	PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2019, 11, 695.	1.7	12
92	TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Annals of Diagnostic Pathology, 2019, 41, 38-42.	0.6	18
93	Patient with mixed-phenotype acute leukemia with CBFB rearrangement. Leukemia and Lymphoma, 2019, 60, 2829-2831.	0.6	0
94	NPM1mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information inNPM1â€mutated acute myeloid leukemia. American Journal of Hematology, 2019, 94, E158-E160.	2.0	17
95	DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and highâ€risk disease. American Journal of Hematology, 2019, 94, 757-766.	2.0	86
96	Routine sequencing in <scp>CLL</scp> has prognostic implications and provides new insight into pathogenesis and targeted treatments. British Journal of Haematology, 2019, 185, 852-864.	1.2	19
97	Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. American Journal of Surgical Pathology, 2019, 43, 1429-1437.	2.1	59
98	Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica, 2019, 104, 305-311.	1.7	56
99	Ultra-Rapid Reporting of GENomic Targets (URGENTseq). Journal of Molecular Diagnostics, 2019, 21, 89-98.	1.2	23
100	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematology,the, 2019, 6, e29-e37.	2.2	84
101	Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. Blood Cancer Journal, 2019, 9, 7.	2.8	64
102	Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML). Blood, 2019, 134, 1309-1309.	0.6	9
103	Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). Blood, 2019, 134, 678-678.	0.6	26
104	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. Blood, 2019, 134, 2723-2723.	0.6	14
105	Expression Profiling of mRNA By Next Generation Sequencing and the Development of Algorithm for Predicting Response in Acute Myeloid Leukemia. Blood, 2019, 134, 1314-1314.	0.6	0
106	Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia. Blood, 2019, 134, 2730-2730.	0.6	0
107	Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. American Journal of Surgical Pathology, 2018, 42, 799-806.	2.1	29
108	Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement. Aesthetic Surgery Journal, 2018, 38, .	0.9	5

#	Article	IF	Citations
109	Chronic lymphoproliferative disorder of NKâ€cells: A singleâ€institution review with emphasis on relative utility of multimodality diagnostic tools. European Journal of Haematology, 2018, 100, 444-454.	1.1	17
110	3q26/ EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. Leukemia Research, 2018, 65, 25-28.	0.4	6
111	Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. American Journal of Surgical Pathology, 2018, 42, 492-499.	2.1	14
112	Mutational landscape of myelodysplastic/myeloproliferative neoplasmâ€“unclassifiable. Blood, 2018, 132, 2100-2103.	0.6	40
113	Recent Updates on Chronic Myelomonocytic Leukemia. Current Hematologic Malignancy Reports, 2018, 13, 446-454.	1.2	6
114	Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget, 2018, 9, 10259-10271.	0.8	29
115	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Advances, 2018, 2, 1807-1816.	2.5	34
116	Characterization of chronic myelomonocytic leukemia with TP53 mutations. Leukemia Research, 2018, 70, 97-99.	0.4	8
117	Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Human Pathology, 2018, 82, 215-231.	1.1	11
118	A multimodality workâ€up of patients with Hypereosinophilia. American Journal of Hematology, 2018, 93, 1337-1346.	2.0	14
119	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapseâ€free survival. American Journal of Hematology, 2018, 93, 1376-1383.	2.0	17
120	Mixed Cytoses and Cytopenias. , 2018, , 257-279.		0
121	Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. American Journal of Dermatopathology, 2018, 40, 831-835.	0.3	1
122	Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood, 2018, 132, 84-84.	0.6	6
123	Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. Blood, 2018, 132, 3983-3983.	0.6	2
124	Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget, 2018, 9, 8441-8449.	0.8	27
125	RAS and TP53, Not NOTCH1, Can Predict Survival in Adults with Acute T-Cell Lymphoblastic Leukemia Treated with Hypercvad. Blood, 2018, 132, 4085-4085.	0.6	0
126	Myeloid neoplasms with concurrent BCRâ€ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm. American Journal of Hematology, 2017, 92, 520-528.	2.0	23

#	Article	IF	Citations
127	Immunophenotypic Shifts in Primary Cutaneous Î³Î´ T-Cell Lymphoma Suggest Antigenic Modulation. American Journal of Surgical Pathology, 2017, 41, 431-445.	2.1	12
128	Characteristics and clinical implications of reactive germinal centers in the bone marrow. Human Pathology, 2017, 68, 7-21.	1.1	4
129	Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature. Histopathology, 2017, 70, 821-831.	1.6	12
130	Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence. Blood, 2017, 129, 1563-1563.	0.6	10
131	Prognostic impact of <scp>CD</scp>5 expression in diffuse large Bâ€cell lymphoma in patients treated with rituximabâ€<scp>EPOCH</scp>. European Journal of Haematology, 2017, 98, 415-421.	1.1	41
132	Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. Journal of Cutaneous Pathology, 2017, 44, 1075-1079.	0.7	27
133	Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica, 2017, 102, 1661-1670.	1.7	64
134	High-grade Transformation of Low-grade B-cell Lymphoma. American Journal of Surgical Pathology, 2016, 40, e1-e16.	2.1	19
135	A rare histologic variant of a common lymphoma. Blood, 2016, 128, 3012-3012.	0.6	0
136	Preleukemic phase of chronic myelogenous leukemia: morphologic and immunohistochemical characterization of 7 cases. Annals of Diagnostic Pathology, 2016, 21, 53-58.	0.6	11
137	Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leukemia and Lymphoma, 2016, 57, 2804-2812.	0.6	46
138	CAL2 Immunohistochemical Staining Accurately IdentifiesCALRMutations in Myeloproliferative Neoplasms. American Journal of Clinical Pathology, 2016, 146, 431-438.	0.4	17
139	Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. American Journal of Hematology, 2016, 91, 1036-1043.	2.0	38
140	How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 787-792.	2.3	4
141	Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. American Journal of Clinical Pathology, 2016, 145, 418-427.	0.4	6
142	DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 1969-1973.	0.6	3
143	Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leukemia and Lymphoma, 2016, 57, 1104-1113.	0.6	40
144	Quantitative PCR for Plasma Epstein-Barr Virus Loads in Cancer Diagnostics. Methods in Molecular Biology, 2016, 1392, 51-61.	0.4	3

#	Article	IF	Citations
145	Myeloproliferative Neoplasms with Calreticulin Mutations Exhibit Distinctive Morphologic Features. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S57.	0.2	0
146	Unusual breast mass: lymphoma with crystal-storing histiocytosis. Blood, 2015, 125, 2445-2445.	0.6	4
147	Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood, 2015, 125, 3360-3363.	0.6	22
148	Disseminated blastic plasmacytoid dendritic cell neoplasm. Blood, 2015, 126, 558-558.	0.6	7
149	Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. Journal of Hematology and Oncology, 2015, 8, 65.	6.9	102
150	WaldenstrÃ¶m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. Journal of Hematology and Oncology, 2015, 8, 74.	6.9	15
151	Durable remission with rituximab in a patient with an unusual variant of <scp>C</scp>astleman's disease with myelofibrosisâ€"<scp>TAFRO</scp> syndrome. American Journal of Hematology, 2015, 90, 1091-1092.	2.0	26
152	Phase <scp>II</scp> study of <scp>HCVIDD</scp>/<scp>MA</scp> in patients with newly diagnosed peripheral Tâ€cell lymphoma. British Journal of Haematology, 2015, 171, 509-516.	1.2	15
153	Epsteinâ€"Barr virusâ€positive plasmacytoma in immunocompetent patients. Histopathology, 2015, 67, 225-234.	1.6	31
154	Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Human Pathology, 2015, 46, 558-569.	1.1	43
155	Clinical Validation of a Multipurpose Assay for Detection and Genotyping ofCALRMutations in Myeloproliferative Neoplasms. American Journal of Clinical Pathology, 2015, 144, 746-755.	0.4	8
156	<scp>TP</scp>53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. British Journal of Haematology, 2015, 171, 91-99.	1.2	43
157	B-Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. American Journal of Clinical Pathology, 2015, 144, 393-410.	0.4	56
158	Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of Î³Î´ T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With Î³Î´ T-Cell Large Granular Lymphocytic Leukemia. American Journal of Clinical Pathology, 2015, 144, 607-619.	0.4	34
159	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Modern Pathology, 2015, 28, 373-382.	2.9	28
160	Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. Journal of Hematology and Oncology, 2014, 7, 74.	6.9	90
161	Intrauterine Growth Restriction Caused by Underlying Congenital Cytomegalovirus Infection. Journal of Infectious Diseases, 2014, 209, 1573-1584.	1.9	95
162	Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. Modern Pathology, 2014, 27, 1468-1478.	2.9	54

#	Article	IF	Citations
163	Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. Journal of Hematology and Oncology, 2014, 7, 26.	6.9	15
164	Clinical and Biological Features of Primary Testicular B-Cell Lymphoma - a Single-Institution Study of 89 Cases. Blood, 2014, 124, 3036-3036.	0.6	0
165	MYC Expression Is Prognostic in Therapy Related Acute Myeloid Leukemia (AML) and AML with Myelodysplastic Syndrome (MDS)-Related Changes. Blood, 2014, 124, 5334-5334.	0.6	0
166	CINtecÂ® PLUS dual immunostain: A triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion. Diagnostic Cytopathology, 2013, 41, 582-587.	0.5	36
167	Multimodality Evaluation of a Rare Intracardiac Tumor: Cardiac Hemangioma. American Journal of Medicine, 2011, 124, e3-e4.	0.6	3
168	Polyomavirus infection and urothelial carcinoma. Diagnostic Cytopathology, 2011, 39, 531-535.	0.5	10
169	Chemokine-Like Receptor-1 Expression by Central Nervous System-Infiltrating Leukocytes and Involvement in a Model of Autoimmune Demyelinating Disease. Journal of Immunology, 2009, 183, 6717-6723.	0.4	70
170	Dopamine receptor mechanism(s) and antinociception and tolerance induced by swim stress in formalin test. Behavioural Pharmacology, 2006, 17, 341-347.	0.8	7
171	Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Modern Pathology, 0, , .	2.9	0